New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging

Disease Markers

Volumn 34, Issue 5, 2013, Pages 341-348

  Palavra, Filipe ^a,b   Marado, Daniela ^a   Mascarenhas Melo, Filipa ^b   Sereno, José ^b   Teixeira Lemos, Edite ^c   Nunes, Carla Cecília ^a   Gonçalves, Grilo ^a   Teixeira, Frederico ^b   Reis, Flávio ^b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

Author keywords

early cardiovascular risk; EDSS; Multiple sclerosis; oxidized LDL; small HDL; VEGF

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; SCORING SYSTEM; STAGING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84878866094     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/567162     Document Type: Article

References (34)

1. World Health Organization: Atlas Multiple Sclerosis Resources in the World. Geneva, WHO 2008, http://www. who. int/mental-health/neurology/Atlas-MS- WEB. pdf (accessed on 20 July 2012).
2. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727-39.
3. Acevedo AR, Nava C, Arriada N, Violante A, Corona T. Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand. 2000;101(2):85-8.
4. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: A population-based cohort study. Neuroepidemiology. 2010;35(4):267-74.
5. Ranadive SM, Yan H, Weikert M, Lane AD, Linden MA, Baynard T, Motl RW, Fernhall B. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012;44(2):238-43.
6. Merkelbach S, Haensch CA, Hemmer B, Koehler J, König NH, Ziemssen T. Multiple sclerosis and the autonomic nervous system. J Neurol. 2006;253 Suppl 1:I21-5.
7. Sanya EO, Tutaj M, Brown CM, Goel N, Neundörfer B, Hilz MJ. Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients. Clin Auton Res. 2005;15(3):213-8.
8. Olindo S, Guillon B, Helias J, Phillibert B, Magne C, Fève JR. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol. 2002;9(3):287-91.
9. Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, Scott GS, Murray D, Bremner WF, Third JL, Johnson MC, Foley S, Van Cauteren J, Shah F, Shirazi P, Nemchausky BA, Hooper DC. Altered circadian relationship between serum nitric oxide, carbon dioxide, and uric acid in multiple sclerosis. Chronobiol Int. 2004;21(4-5):739-58.
10. Mirshafiey A, Jadidi-Niaragh F. Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol. 2010;32(4):543-54.
11. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, Teter B, Hussein S, Mehta B, Weiskopf M, Durfee J, Bergsland N, Ramanathan M. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation. 2011;4(8):127.
12. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: Potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004;4(4): 211-217.
13. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17(36):4511-20.
14. Huang SS, Huang PH, Chen YH, Chiang KH, Chen JW, Lin SJ. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J Atheroscler Thromb. 2010;17(3):295-303.
15. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist. 2010;15(7):683-94.
16. Iacobaeus E, Amoudruz P, Ström M, Khademi M, Brundin L, Hillert J, Kockum I, Malmström V, Olsson T, Tham E, Piehl F. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS One. 2011;6(5):e19138.
17. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
18. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
19. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000;275(33):25616-24.
20. Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider WJ, Nimpf J. The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2. J Biol Chem. 2000;275(33):25625-32.
21. Borghini I, Barja F, Pometta D, James RW. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochem Biophys Acta. 1995; 1255(2):192-200.
22. Cybulsky MI, Jr. Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogen esis. Science. 1991; 251(4995):788-791.
23. Stokes KY, Calahan L, Hamric CM, Russell JM, Granger DN. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol. 2009;296(3):H689-97.
24. Minagar A, Jy W, Jimenez JJ, Alexander JS. Multiple sclerosis as a vascular disease. Neurol Res. 2006;28(3):230-5.
25. De Keyser J, Steen C, Mostert JP, Koch MW. Hypoperfusion of the cerebral white matter in multiple sclerosis: Possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab. 2008;28(10):1645-51.
26. Huang H, Ma R, Liu D, Liu C, Ma Y, Mai W, Dong Y. Oxidized low-density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease. Dis Markers. 2012 Oct 22. [Epub ahead of print].
27. Huang Y, Hu Y, MaiW, Cai X, Song Y, Wu Y, Dong Y, Huang H, He Z, Li W, Yang Y, Rao S. Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease. Dis Markers. 2011;31(5):295-301.
28. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607-8.
29. Markovic-Plese S, Jewells V, Speer D. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2009;72(22):1965-6.
30. Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stüve O. The combination of interferon-beta and HMG-CoA reductase inhibition inmultiple sclerosis: Enthusiasm lost too soon? CNS Neurosci Ther. 2010;16(6):362-73.
31. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989-93.
32. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. ITN STAyCIS Study Group; ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study. Neurology. 2012; 78(15):1171-8.
33. Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB. SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon ?-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691-701.
34. Soilu-Hänninen M, Koskinen JO, Laaksonen M, Hänninen A, Lilius EM, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology. 2005;65(1):153-5.